Everus Construction acquires SE&M Constructors for $158 million

Everus acquired SE&M for $158 million in cash (plus an earnout up to 8% of the purchase price); SE&M had $109M revenue in 2025 with EBITDA margins in the high teens and recurring maintenance/retrofit exposure (≈65% mechanical, 60% pharma/healthcare). Everus reported Q4 2025 EPS of $1.08 vs $0.69 expected and revenue of $1.01B (+33% YoY), expects pro forma net leverage of 0.8x post-deal, and will update 2026 guidance in Q1; 2025 capex was <1% of SE&M revenue. Analysts reacted positively with Freedom Capital Markets raising its PT to $138 from $110 (Buy) and Cantor Fitzgerald raising its PT to $115 from $97 (Neutral), reflecting improved investor sentiment around demand visibility and backlog.

Analysis

Everus’s bolt‑on accelerates a shift in revenue mix toward higher-margin, recurring MEP maintenance work versus new-build contracting; that structural tilt should compress revenue volatility but places a premium on workforce utilization and aftermarket pricing power. With management continuity and low incremental capex needs, the path to FCF expansion is plausible, but the real lever is cross‑sell and SG&A dilution — expect meaningful margin moves to play out over 6–18 months as integration synergies are realized.

Second‑order winners include regional specialty subcontractors and spare‑parts suppliers for pharmaceutical facilities (higher backlog converts into steady parts/service demand), while national new‑build contractors could lose high-margin retrofit work in Southeast pharma corridors. Key near‑term risks are wage inflation for skilled craft, backlog conversion slippage, and working‑capital timing that can flip stated EBITDA improvements into late cash conversion — these are 0–12 month execution risks that materially affect valuation.

Catalysts: an updated 2026 guide and Q1 call commentary (next 0–3 months) will reprice conviction; subsequent 3–12 month quarters will reveal whether margin improvement is sustained or one‑off. Countervailing scenarios that reverse the upside include a pharma capex pause or outsized integration costs; either would pressure multiples quickly given the stock’s sensitivity to perceived growth/recurring revenue profiles.

Consensus is underweighting cash conversion and labor cost risk while overemphasizing backlog as safety. If management delivers clean, quantified synergy milestones and steady cash flow conversion in the next two quarters, upside is underappreciated; if not, multiple contraction is rapid because the thesis rests on execution rather than market share gains alone.

Key Decisions for Investors

• Long ECG equity (size 1–2% portfolio) horizon 6–12 months: target +30–40% upside if margin conversion shows +200–300bps improvement; set protective stop at -12–15% to cap integration execution risk.
• Options: buy a 9–12 month 15–20% OTM call spread on ECG (debit) to leverage upside while capping premium outlay. Reward scenario: 3x+ return if Q1 guide and two subsequent quarters confirm margin trajectory; max loss = premium paid (~100% of option cost).
• Pair trade (market‑neutral): long ECG / short FLR (equal dollar) for 6–12 months to capture premium for recurring maintenance exposure vs cyclical new‑build exposure. Expected outperformance 10–20% if maintenance backlog converts and general contractor cycle softens; key risk is a broad construction re‑acceleration that lifts FLR.
• Event hedge ahead of Q1 guidance: buy 1–3 month puts (or collar) on a 0.5–1% position to protect against an adverse guide/cash conversion miss. Cost justified given binary nature of guidance release with high information content.